Mitochondria and Mustard Damage at the Ocular Surface

眼表的线粒体和芥末损伤

基本信息

  • 批准号:
    10708498
  • 负责人:
  • 金额:
    $ 53.74万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2023
  • 资助国家:
    美国
  • 起止时间:
    2023-09-01 至 2026-08-31
  • 项目状态:
    未结题

项目摘要

PROJECT SUMMARY Ocular surface (OcS) exposure to the chemical warfare vesicant sulfur mustard (SM), or its analogue nitrogen mustard (NM), causes immediate tissue damage and long-term pathology. Current medical countermeasures (MCMs) frequently result in incomplete or transient efficacy. Excessive accumulation of reactive oxygen species (ROS) induces oxidative stress (OXS), which plays prominently in OcS epithelial damage from a variety of causes, including exposure to SM and analogues. ROS are produced by mitochondria. It is known that mitochondria are damaged by exposure to SM analogues, but mechanisms leading to OXS are under- explored. Recently, the project team made the unexpected discovery that dynasore and dyngo-4a, small molecules that target dynamin family proteins involved in mitochondrial homeostasis, are remarkably protective against OXS due to hydrogen peroxide (HP) exposure in an OcS epithelial cell culture model. In a follow-up study, they identified a novel pathway whereby dynasore protects by inhibiting Ca2+ influx, shifting activity of the unfolded protein response (UPR) towards homeostasis and inhibiting mitochondrial transition pore (mPTP) opening. In Preliminary Data presented herein, they now show that NM exposure also induces the UPR in the cell culture model, but dynasore is not protective. Interestingly, another small molecule inhibitor of dynamins is protective: mdivi-1. Signficantly, mdivi-1 did not shift the UPR towards homeostasis in NM-exposed cells and did not protect against HP exposure. These results indicate that mechanisms leading to OXS after exposure to HP or NM must be different, and that elucidating the mechanism of mDivi-1 counteraction may provide important insight into how NM damages cells. Mdivi-1 has been widely considered to be a specific inhibitor of the mitochondrial-localized dynamin DRP1. However, it was recently reported that mdivi-1 also directly targets mitochondrial energetics. The objective of this project is to investigate mitochondrial mechanisms in OcS exposure to NM, the relationship to HP exposure, and mechanisms of OcS protection by mdivi-1. The team will employ a well-established human corneal epithelial cell culture model. To ensure scientific rigor, primary human corneal epithelial cells will be used to validate key results in vitro, and a mouse model will provide in vivo validation. To add an innovative dimension, live cell evaluative methods and discovery techniques will be applied, including Ca2+ imaging, mitochondrial imaging, cell-based reporter constructs, transgenic reporter mice, RNA-seq and single cell RNA-seq (scRNA-seq). Results of the planned study will provide new knowledge about how NM exposure leads to OXS. Mdivi-1 has the unusual capacity to attenuate pathological ROS production while having limited impact on ROS in healthy cells, making it uniquely attractive as a potential MCM.
项目摘要 眼表(OcS)暴露于化学战发泡剂硫芥(SM)或其类似物氮 芥子气(NM),造成即时组织损伤和长期病理。当前的医疗对策 (MCMs)通常导致不完全或短暂的疗效。活性氧过度积累 活性氧(ROS)诱导氧化应激(OXS),这在OXS上皮损伤中起着重要作用。 各种原因,包括暴露于SM和类似物。ROS由线粒体产生。已知 暴露于SM类似物会损伤线粒体,但导致OXS的机制尚不清楚。 探讨了最近,项目组意外地发现,dynasore和dyngo-4a,小 靶向参与线粒体稳态的动力蛋白家族蛋白的分子, 在OcS上皮细胞培养模型中,由于过氧化氢(HP)暴露,OXS的抗氧化性降低。新闻和跟踪 在这项研究中,他们确定了一种新的途径,dynasore通过抑制Ca 2+内流,改变 未折叠蛋白反应(UPR)对稳态和抑制线粒体过渡孔(mPTP) 开放后在本文提供的初步数据中,他们现在表明NM暴露也诱导了 细胞培养模型,但dynasore没有保护作用。有趣的是,动力蛋白的另一种小分子抑制剂是 保护:mdivi-1。明显地,在NM暴露的细胞中,mdivi-1没有使UPR向稳态转变, 不能防止HP暴露。这些结果表明,暴露后导致OXS的机制, HP或NM必须是不同的,并且阐明mDivi-1抵消作用的机制可以提供 对NM如何损害细胞的重要见解。Mdivi-1已被广泛认为是一种特异性抑制剂, 大脑中的发动蛋白DRP 1然而,最近有报道称, 线粒体能量学本项目的目的是研究线粒体机制, OcS暴露于NM,与HP暴露的关系,以及mdivi-1对OcS保护的机制。 该团队将采用一种成熟的人类角膜上皮细胞培养模型。为了确保科学严谨, 原代人角膜上皮细胞将用于验证体外关键结果,小鼠模型将 提供体内验证。为了增加一个创新的维度,活细胞评估方法和发现 技术将被应用,包括Ca 2+成像,线粒体成像,基于细胞的报告构建体, 转基因报告小鼠、RNA-seq和单细胞RNA-seq(scRNA-seq)。计划研究的结果将 提供有关NM暴露如何导致OXS的新知识。Mdivi-1具有非同寻常的能力, 病理性ROS产生,同时对健康细胞中的ROS具有有限的影响,使其具有独特的吸引力, 作为潜在的MCM。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

M. Elizabeth Fini其他文献

M. Elizabeth Fini的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('M. Elizabeth Fini', 18)}}的其他基金

Dynasore Analogues for Ocular Surface Protection
用于眼表保护的 Dynasore 类似物
  • 批准号:
    10310762
  • 财政年份:
    2019
  • 资助金额:
    $ 53.74万
  • 项目类别:
Dynasore Analogues for Ocular Surface Protection
用于眼表保护的 Dynasore 类似物
  • 批准号:
    10004039
  • 财政年份:
    2019
  • 资助金额:
    $ 53.74万
  • 项目类别:
Protection and Treatment of the Ocular Surface Barrier
眼表屏障的保护和治疗
  • 批准号:
    9334035
  • 财政年份:
    2017
  • 资助金额:
    $ 53.74万
  • 项目类别:
Discovery Approach to Ocular Hypertension
高眼压症的发现方法
  • 批准号:
    9921393
  • 财政年份:
    2017
  • 资助金额:
    $ 53.74万
  • 项目类别:
Discovery Approach to Ocular Hypertension
高眼压症的发现方法
  • 批准号:
    9333672
  • 财政年份:
    2017
  • 资助金额:
    $ 53.74万
  • 项目类别:
Discovery Approach to Ocular Hypertension
高眼压症的发现方法
  • 批准号:
    9751867
  • 财政年份:
    2017
  • 资助金额:
    $ 53.74万
  • 项目类别:
Clusterin at the Ocular Surface
眼表面的聚集蛋白
  • 批准号:
    9329433
  • 财政年份:
    2016
  • 资助金额:
    $ 53.74万
  • 项目类别:
Clusterin at the Ocular Surface
眼表面的聚集蛋白
  • 批准号:
    9196261
  • 财政年份:
    2016
  • 资助金额:
    $ 53.74万
  • 项目类别:
Clusterin at the Ocular Surface
眼表面的聚集蛋白
  • 批准号:
    9755442
  • 财政年份:
    2016
  • 资助金额:
    $ 53.74万
  • 项目类别:
Miami Center for Vision Research
迈阿密视觉研究中心
  • 批准号:
    6888034
  • 财政年份:
    2004
  • 资助金额:
    $ 53.74万
  • 项目类别:

相似海外基金

Studies of Chemically Labile Alkylation Damage in DNA
DNA 中化学不稳定烷基化损伤的研究
  • 批准号:
    10735154
  • 财政年份:
    2023
  • 资助金额:
    $ 53.74万
  • 项目类别:
The role of histidine phosphorylation in the DNA alkylation damage response
组氨酸磷酸化在 DNA 烷基化损伤反应中的作用
  • 批准号:
    10581923
  • 财政年份:
    2023
  • 资助金额:
    $ 53.74万
  • 项目类别:
Studies of Chemically Labile Alkylation Damage in DNA
DNA 中化学不稳定烷基化损伤的研究
  • 批准号:
    10769108
  • 财政年份:
    2023
  • 资助金额:
    $ 53.74万
  • 项目类别:
DABCO and Quinuclidine as HAT Catalysts in Direct Arylation and Alkylation of Aldehyde's C-H Bonds via Photoredox Catalysis: A computational stud
DABCO 和奎宁环作为 HAT 催化剂通过光氧化还原催化醛的 C-H 键直接芳基化和烷基化:一项计算研究
  • 批准号:
    2876395
  • 财政年份:
    2022
  • 资助金额:
    $ 53.74万
  • 项目类别:
    Studentship
CAREER: Engineered SAM-Dependent Enzymes for Stereoselective Alkylation Reactions
职业:用于立体选择性烷基化反应的工程 SAM 依赖性酶
  • 批准号:
    2145749
  • 财政年份:
    2022
  • 资助金额:
    $ 53.74万
  • 项目类别:
    Standard Grant
Characterizing the role of RNF25 in repair of DNA alkylation in blood cancers
表征 RNF25 在血癌 DNA 烷基化修复中的作用
  • 批准号:
    10438061
  • 财政年份:
    2022
  • 资助金额:
    $ 53.74万
  • 项目类别:
Characterizing the role of RNF25 in repair of DNA alkylation in blood cancers
表征 RNF25 在血癌 DNA 烷基化修复中的作用
  • 批准号:
    10580070
  • 财政年份:
    2022
  • 资助金额:
    $ 53.74万
  • 项目类别:
Ketone Alkylation Using Simple Olefins: A Sustainable Chemistry Approach
使用简单烯烃进行酮烷基化:一种可持续的化学方法
  • 批准号:
    2154632
  • 财政年份:
    2022
  • 资助金额:
    $ 53.74万
  • 项目类别:
    Standard Grant
Alkyl(aryl)iodonium Reagents for Late-Stage Alkylation
用于后期烷基化的烷基(芳基)碘鎓试剂
  • 批准号:
    EP/W00934X/1
  • 财政年份:
    2022
  • 资助金额:
    $ 53.74万
  • 项目类别:
    Research Grant
Development of New Methods for Asymmetric Synthesis and Nitrogen Fixation by using dihydropyridine derivatives as Alkylation Reagents
以二氢吡啶衍生物为烷基化试剂开发不对称合成和固氮新方法
  • 批准号:
    22J14253
  • 财政年份:
    2022
  • 资助金额:
    $ 53.74万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了